Health-economic burden attributable to novel serotypes in candidate 24- and 31-valent pneumococcal conjugate vaccines

Author:

King Laura MORCID,Lewnard Joseph A

Abstract

ABSTRACTBackgroundNext-generation pneumococcal vaccines currently in clinical trials include 24- and 31-valent pneumococcal conjugate vaccines (PCV24, PCV31), which aim to prevent upper-respiratory carriage and disease involving the targeted serotypes. We aimed to estimate the comprehensive health-economic burden associated with acute respiratory infections (ARIs) and invasive pneumococcal disease (IPD) attributable to PCV24- and PCV31-additional (non-PCV20) serotypes in the United States.MethodsWe multiplied all-cause incidence rate estimates for acute otitis media (AOM), sinusitis, and non-bacteremic pneumonia by estimates of the proportions of each of these conditions attributable to pneumococci and the proportions of pneumococcal infections involving PCV24- and PCV31-additional serotypes. We obtained serotype-specific IPD incidence rates from US Active Bacterial Core surveillance data. We accounted for direct medical and non-medical costs associated with each condition to estimate resulting health-economic burden. Non-medical costs included missed work and lost quality-adjusted life years due to death and disability.ResultsThe health-economic burden of PCV24-additional serotypes totaled $1.3 billion ($1.1-1.7b) annually in medical and non-medical costs, comprised of $0.9b ($0.7-1.2b) due to ARIs and $0.4b ($0.3-0.5b) due to IPD. For PCV31-additional serotypes, medical and non-medical costs totaled $7.5b ($6.6-8.6b) annually, with $5.5b ($4.7-6.6b) due to ARIs and $1.9b ($1.8-2.1b) due to IPD. The largest single driver of costs was non-bacteremic pneumonia, particularly in adults aged 50-64 and ≥65 years.ConclusionsAdditional serotypes in PCV24 and PCV31, especially those included in PCV31, account for substantial health-economic burden in the United States.SummaryNovel serotypes in 24- and 31-valent pneumococcal conjugate vaccines, currently in clinical trials, account for substantial health-economic burdens in the United States, especially in adults ≥50 years. Vaccines targeting these serotypes may prevent pneumococcal disease and reduce associated costs.

Publisher

Cold Spring Harbor Laboratory

Reference42 articles.

1. Outpatient Visits and Antibiotic Use Due to Higher-Valency Pneumococcal Vaccine Serotypes

2. Centers for Disease Control and Prevention. Bact Facts: Streptococcus pneumoniae. Accessed March 8, 2022. https://app.powerbigov.us/view?r=eyJrIjoiNjc5OGRjODctNWQ5ZC00ZWEwLWI5ZjgtNGI3ZmFhODVmYTlhIiwidCI6IjljZTcwODY5LTYwZGItNDRmZC1hYmU4LWQyNzY3MDc3ZmM4ZiJ9&pageName=ReportSectione93482d78e7dc3ed111b

3. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis

4. Twenty-Year Public Health Impact of 7- and 13-Valent Pneumococcal Conjugate Vaccines in US Children

5. Cost-effectiveness of pneumococcal conjugate vaccine: An update after 7 years of use in the United States

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3